Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

SG&A

Legal contingencies

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Illumina

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Illumina reports robust earnings, eyes GRAIL divestiture and market expansion

Illumina's strong financial performance in Q4 2022 and full-year revenue, driven by instrument placements and successful product launches, positions the company for continued growth.
Challenges such as margin decline, potential divestiture of GRAIL, and significant investment in clinical trials need to be managed strategically for sustained profitability.
Opportunities lie in revenue growth projections, NovaSeq X's market acceptance, GRAIL's product expansion, and continued FDA collaboration for product credibility.
Overall, Illumina's focus on innovation, market expansion, and operational efficiency sets a positive trajectory for future growth and market leadership.

Illumina surpasses Q1 revenue expectations, eyes margin improvement

Illumina's Q1 performance exceeded expectations with strong clinical demand and key product milestones driving revenue growth.
Despite challenges like Russia headwinds and regulatory uncertainties, Illumina aims for margin improvement and sustained revenue growth.
Opportunities lie in cost reduction, gross margin improvement, and product innovations to drive future growth and profitability.
Overall, Illumina's strategic focus on clinical markets and cost efficiencies positions it for continued success and market leadership.

Illumina adjusts revenue guidance for 2023 amidst challenges and opportunities

Illumina faces challenges in revenue growth for 2023 but remains committed to margin improvement. The company is navigating through cautious customer behaviors and challenges in China while focusing on innovation and cost reduction. Opportunities lie in strong customer interest in new products and the long-term potential of the China market.

Illumina faces revenue challenges in Q3 2023 amidst growth opportunities

Illumina's Q3 performance was steady, but challenges in the macroeconomic environment and GRAIL's performance pose concerns for future revenue and growth.
Despite these challenges, Illumina remains committed to driving top-line growth through innovation and operational excellence, aiming for swift decisions on GRAIL's future.
Opportunities lie in margin improvements, growth potential compared to peers, and strategic decisions for GRAIL funding, indicating a path forward amidst challenges.
The company faces headwinds in consumables sales and Nova X transition but sees a positive outlook for long-term market positioning and growth opportunities.

Illumina reports $1.12B revenue, eyes multiomics expansion opportunities

Illumina's Q4 performance showed revenue growth and successful NovaSeq X launch, but faced challenges in Greater China.
The company's strengths lie in customer relationships, innovation pipeline, and plans to enter the multiomics space.
Opportunities include expanding into proteomics, driving fleet expansions, and developing MRD assay applications.

Illumina surpasses Q1 revenue expectations, eyes growth in XLEAP chemistry

Illumina's Q1 performance exceeded expectations with strong revenue and service growth. The company's focus on innovation, strategic partnerships, and customer-centricity positions it well for future growth. While facing challenges in operating expenses and market dynamics, Illumina sees opportunities in XLEAP chemistry adoption and increased instrument orders.

Illumina reports solid Q2 revenue amidst regional challenges and innovation

Illumina's Q2 2024 performance reflected strong Core revenue driven by sequencing consumables and placements.
While facing challenges in regional revenue declines, the company's strengths in genomics support and innovation remain key.
Opportunities for growth exist through customer adoption trends, operational enhancements, and strategic initiatives.

Illumina reports robust Q3 earnings, eyes genomics innovation for growth

Illumina's Q3 performance was solid, with revenue meeting expectations and strong operational metrics.
While facing challenges in certain regions, the company's focus on innovation and customer collaboration bodes well for future growth.
Opportunities in new product introductions and genomic solutions signal a promising outlook for Illumina's market position.

Revenue

Cost of revenue

Gross profit

Operating expenses

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Core Illumina revenue of $1.09 billion for Q2 2024, down 6% from Q2 2023 (down 6% on a constant currency basis) and up 3% from Q1 2024 Core Illumina GAAP operating margin of 40.5% and non-GAAP operating margin of 22.2% for Q2 2024 Core Illumina GAAP diluted earnings per share of $0.41 and non-GAAP diluted earnings per share of $1.09 for Q2 2024 Lowered fiscal year 2024 Core Illumina revenue guidance to decline 2% to 3% (down 1.5% to 2.5% in constant currency) from 2023 Raised Core Illumina non-GAAP operating margin guidance to a range of 20.5% to 21% for fiscal year 2024 Introducing guidance for Core Illumina non-GAAP diluted earnings per share in the range of $3.80 to $3.95 for fiscal year 2024 On June 24, 2024, we completed the spin-off of GRAIL into a new public company SAN DIEGO , Aug. 6, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2024, which include the consolidated financial results for GRAIL through June 24, 2024. "The Illumina team delivered results ahead of our expectations in the quarter, driven by disciplined execution on our strategic priorities," said Jacob Thaysen, Chief Executive Officer.

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2024

Delivers Illumina's flagship oncology products on its most powerful sequencers to enable comprehensive genomic profiling at greater scale and at lower overall costs for customers SAN DIEGO , Aug. 5, 2024 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has expanded its oncology menu for NovaSeq™ X Series customers. The company began offering the newly verified high-throughput version of TruSight™ Oncology 500 (TSO 500 HT), and the latest version of its distributed liquid biopsy research assay, TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2), in recent months.

Illumina launches new oncology menu for NovaSeq X Series customers

Genmab - ADR

Two biotech bigwigs set to beat on earnings next week are: ILMN, GMAB.

Buy 2 Biotech Bigwigs Set to Gain on Possible Earnings Beat

Get a deeper insight into the potential performance of Illumina (ILMN) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Stay Ahead of the Game With Illumina (ILMN) Q2 Earnings: Wall Street's Insights on Key Metrics

Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Illumina (ILMN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Illumina (ILMN) Could Beat Earnings Estimates Again

The consensus price target hints at a 27% upside potential for Illumina (ILMN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts Think Illumina (ILMN) Could Surge 27.02%: Read This Before Placing a Bet

Adaptive Biotechnologies

Guardant Health Inc

Two elements favor the case for acquiring precision medicine stocks. First, the obvious point: barring extraordinary circumstances, the broader healthcare ecosystem will always be relevant.

3 Precision Medicine Stocks Tailoring Treatments

SAN DIEGO , July 18, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ: ILMN) previously announced on June 24, the company will present a Strategy Update on Tuesday, August 13, 2024 starting at 8:00am Pacific Time. The event will feature presentations by members of Illumina's executive team and conclude with a Q&A session.

Illumina to Present Upcoming Strategy Update

SAN FRANCISCO--(BUSINESS WIRE)-- #biotech--Illumina Ventures today announced that Timothy Stenzel, MD, PhD, and Jerry Steiner have joined the team as Advisors.

Illumina Ventures Adds Two New Experts as Advisors

Illumina (ILMN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Illumina (ILMN) Upgraded to Buy: Here's Why

Life sciences company Illumina Inc. NASDAQ: ILMN stock surged over 10% following its announcement of the acquisition of Fluent Biosciences. This comes after its divestiture and spin-off of GRAIL, LLC NASDAQ: GRAL on June 24, 2024.

Strategic Buy Lights Up This Biotech Stock: Time to Invest?

Illumina stock (NASDAQ: ILMN) saw a 6% rise on Wednesday, July 10, faring better than its peer — Mettler-Toledo stock – up 1%. The rise in ILMN stock can primarily be attributed to the company's acquisition of Fluent Biosciences to expand its single-cell analysis and multiomics offerings.

What's Happening With Illumina Stock?

SAN DIEGO , July 11, 2024 /PRNewswire/ -- As Illumina, Inc. (NASDAQ:ILMN) previously announced on June 24, the company will issue results for the second quarter 2024 following the close of market on Tuesday, August 6, 2024.  On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.

Illumina to Announce Second Quarter 2024 Financial Results on Tuesday, August 6, 2024

Last month, Illumina Inc ILMN had to let go of Grail Inc. Still, the DNA sequencing company has acquired Fluent BioSciences to expand its reach in single-cell analysis and multiomics research.

Illumina Buys Fluent BioSciences To Gain Stronger Foothold In Single-Cell Analysis

By integrating Fluent's unique technology with Illumina's (ILMN) sequencing and informatics solutions, researchers are likely to gain access to a comprehensive solution for single-cell multiomic analysis.

Illumina (ILMN) Buys Fluent, Grows in Single Cell Research

Accessible, highly scalable single-cell technology  expands Illumina's multiomics capabilities SAN DIEGO , July 9, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, announced that effective today it has acquired Fluent BioSciences, developer of an emerging and highly differentiated single-cell technology.   "The addition of Fluent BioSciences to Illumina will provide significant and new capabilities to our customers in a key growth area and advances our multiomics growth strategy," said Steven Barnard, chief technology officer of Illumina.

Illumina acquires Fluent BioSciences to accelerate single-cell analysis and discovery to a broader customer base

Moderna

Thermo Fisher Scientific

When discussing biotechnology, many focus on medication based on biochemical compounds and their downstream effects. Yet several branches of medical genetics and therapeutics have begun to find novel ways to treat and prevent diseases through gene editing, protein manipulation and overall DNA repair.

3 Biotech Stocks Turning DNA Dreams Into Dollars

Exact Sciences

The personalized medicine market is experiencing significant growth, driven by advancements in genomic technologies and a shift towards more individualized healthcare. In 2024, the market is expected to continue expanding, with projections indicating it could reach approximately $390.65 billion, growing at a compound annual growth rate (CAGR) of around 8.20% from 2024 to 2030.

The 3 Best Personalized Medicine Stocks to Buy in July 2024

The breakup with GRAIL (GRAL) was costly for Illumina (ILMN).

Illumina Takes a $1.47 Billion Charge Related to Its Spinoff of GRAIL

GRAIL Inc

Illumina has finally completed the divestiture of GRAIL, ending a disastrous chapter in its history. The Company paid $8bn to acquire the cancer testing business it helped to create, which proved to be a disastrous mistake, triggering three years of share price losses. Newly spun-out GRAIL faces challenges in the competitive cancer testing market, while Illumina returns to its profitable gene sequencing business.

Illumina: Marriage Made In Hell Is (Finally) Over - Assessing Impact Of GRAIL Spin-Out

Illumina said on Thursday it will take a goodwill impairment charge of $1.47 billion in the second quarter related to the recently spun-off Grail Inc.

Illumina to take $1.47 bln goodwill impairment charge related to Grail in Q2

On June 25, 2024, Illumina, Inc. (NASDAQ: ILMN, $208.92, Market Capitalization: $18.51 billion) announced the completion of the tax free spin-off of GRAIL, Inc. (NASDAQ: GRAL, $36.84, Market Capitalization: $3.26 billion). On June 25, 2024, both the stocks started regular way trading with, new Illumina opening at $108.24, making an intraday high of $112.49, low of $106.26 and closed at $109.84.

Illumina Completes Spin-Off Of GRAIL

GRAIL shares started trading on Nasdaq after a spin-off from Illumina, as the EU's regulatory scrutiny weighed on the prior merger. The company offers the Galleri blood test for early cancer detection, with major sales potential still behind MCED legislation, FDA approval, and medical plan reimbursement implementation. The industry has fierce competition among MCED tests between companies, adding significantly to GRAIL's competitive risks.

GRAIL: Ambitious Illumina Spin-Off Trading At Intriguing Valuation

With the divestment now over, we expect Illumina (ILMN) to soar again on the assumption that the company will start to focus on its legacy businesses.

News for Illumina Stock (ILMN)